148 related articles for article (PubMed ID: 35771033)
41. Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in human breast cancer cells.
Manni A; Washington S; Mauger D; Hackett DA; Verderame MF
Clin Exp Metastasis; 2004; 21(5):461-7. PubMed ID: 15672871
[TBL] [Abstract][Full Text] [Related]
42. Structural insight into DFMO resistant ornithine decarboxylase from Entamoeba histolytica: an inkling to adaptive evolution.
Preeti ; Tapas S; Kumar P; Madhubala R; Tomar S
PLoS One; 2013; 8(1):e53397. PubMed ID: 23326423
[TBL] [Abstract][Full Text] [Related]
43. alpha-Difluoromethylornithine does not antagonize the behavioral effects of putrescine.
Ferchmin PA; Rivera E; Eterović VA
Pharmacol Biochem Behav; 1993 Aug; 45(4):967-71. PubMed ID: 8415838
[TBL] [Abstract][Full Text] [Related]
44. High Performance Photoluminescent Carbon Dots for In Vitro and In Vivo Bioimaging: Effect of Nitrogen Doping Ratios.
Wang J; Zhang P; Huang C; Liu G; Leung KC; Wáng YX
Langmuir; 2015 Jul; 31(29):8063-73. PubMed ID: 26135003
[TBL] [Abstract][Full Text] [Related]
45. Difluoromethylornithine antagonizes taxol cytotoxicity in MCF-7 human breast cancer cells.
Das B; Rao AR; Madhubala R
Oncol Res; 1997; 9(11-12):565-72. PubMed ID: 9563003
[TBL] [Abstract][Full Text] [Related]
46. alpha-Difluoromethylornithine decreases inhibitory transmission in hippocampal slices independently of its inhibitory effect on ornithine decarboxylase.
Ferchmin PA; DiScenna P; Borroni AM; Morales Velez M; Rivera EM; Teyler TJ
Brain Res; 1993 Jan; 601(1-2):95-102. PubMed ID: 8094315
[TBL] [Abstract][Full Text] [Related]
47. Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells.
Schultz CR; Gruhlke MCH; Slusarenko AJ; Bachmann AS
J Nat Prod; 2020 Aug; 83(8):2518-2527. PubMed ID: 32786875
[TBL] [Abstract][Full Text] [Related]
48. Opposing effects of suramin and DL-alpha-difluoromethylornithine on polyamine metabolism contribute to a synergistic action on B16 melanoma cell growth in vitro.
Gritli-Linde A; Björkman U; Delle U; Hultborn R; Johansson BR; Nannmark U; Linde A
Anticancer Res; 1998; 18(2A):863-70. PubMed ID: 9615733
[TBL] [Abstract][Full Text] [Related]
49. Alpha-difluoromethylornithine resistance in Leishmania donovani is associated with increased ornithine decarboxylase activity.
Coons T; Hanson S; Bitonti AJ; McCann PP; Ullman B
Mol Biochem Parasitol; 1990 Feb; 39(1):77-89. PubMed ID: 2154691
[TBL] [Abstract][Full Text] [Related]
50.
Fahmi MZ; Aung YY; Ahmad MA; Kristanti AN; Sakti SCW; Arjasa OP; Lee HV
Nanotheranostics; 2023; 7(3):281-298. PubMed ID: 37064612
[TBL] [Abstract][Full Text] [Related]
51. Local inhibition of ornithine decarboxylase reduces vascular stenosis in a murine model of carotid injury.
Forte A; Grossi M; Turczynska KM; Svedberg K; Rinaldi B; Donniacuo M; Holm A; Baldetorp B; Vicchio M; De Feo M; Santè P; Galderisi U; Berrino L; Rossi F; Hellstrand P; Nilsson BO; Cipollaro M
Int J Cardiol; 2013 Oct; 168(4):3370-80. PubMed ID: 23680596
[TBL] [Abstract][Full Text] [Related]
52. Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway.
Yang J
Br J Cancer; 2024 Mar; 130(4):513-516. PubMed ID: 38316994
[TBL] [Abstract][Full Text] [Related]
53. D,L-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, induces differentiation in MEL cells.
Choudhary SK; Sharma D; Dixit A
Cell Biol Int; 1999; 23(7):489-95. PubMed ID: 10728786
[TBL] [Abstract][Full Text] [Related]
54. Effects of DFMO on glioma cell proliferation, migration and invasion in vitro.
Terzis AJ; Pedersen PH; Feuerstein BG; Arnold H; Bjerkvig R; Deen DF
J Neurooncol; 1998 Jan; 36(2):113-21. PubMed ID: 9525811
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of ornithine decarboxylase activity by small doses of alpha-difluoromethylornithine.
Loprinzi CL; Verma AK
Cancer Lett; 1985 Sep; 28(3):327-33. PubMed ID: 3931903
[TBL] [Abstract][Full Text] [Related]
56. Alpha-difluoromethylornithine-induced inhibition of growth of autochthonous experimental colonic tumors produced by azoxymethane in male F344 rats.
Zhang SZ; Luk GD; Hamilton SR
Cancer Res; 1988 Nov; 48(22):6498-503. PubMed ID: 3141045
[TBL] [Abstract][Full Text] [Related]
57. Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro.
Takigawa M; Enomoto M; Nishida Y; Pan HO; Kinoshita A; Suzuki F
Cancer Res; 1990 Jul; 50(13):4131-8. PubMed ID: 1693880
[TBL] [Abstract][Full Text] [Related]
58. Copper-Doped Carbon Dots for Optical Bioimaging and Photodynamic Therapy.
Wang J; Xu M; Wang D; Li Z; Primo FL; Tedesco AC; Bi H
Inorg Chem; 2019 Oct; 58(19):13394-13402. PubMed ID: 31556604
[TBL] [Abstract][Full Text] [Related]
59. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
60. Reduced cell death in skin flaps in rats treated with difluoromethylornithine.
Gelman J; Bartolome JV; Jenkins S; Serafin D; Schanberg SM; Klitzman B
FASEB J; 1987 Dec; 1(6):474-7. PubMed ID: 3119414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
